Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 11 February 2026 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced its…